Table 3 Gene signature associated to clinical benefit of MAGE-A3 ASCI: Identification in Phase II study in melanoma patients and confirmation in NSCLC patients [17]
| Â | Phase II studies evaluating the MAGE-A3 ASCI | |
|---|---|---|
| Â | Phase II NSCLC (NCT 00290355) | Phase II Melanoma (NCT 00086866) |
GS- | 25% relative improvement (DFI) | OS of 16.2 months |
GS+ | 53% relative improvement (DFI) | OS of 28.0 months |